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Attempts to improve survival following curative surgery for non-small-cell lung cancer are
reviewed. Most of these approaches have been designed to stimulate the resistance of lung
cancer patients in a non-specific fashion. Living bacteria or products of dead bacteria have
been given as adjunctive treatment. Various routes have been used; oral, intradermal, subder-
mal, or intrapleural, with either BCG or Corynebacterium parvum. No reproducible benefit
has been observed. Levamisole has not been proven to be useful. Trials have yet to be com-
pleted to confirm the use of thymosin fraction V for small cell carcinoma in improving the ef-
fectiveness of chemotherapy.
A pilot trial using specific active immunotherapy is described. Prolongation of survival four
years after closure ofthe trial in those patients immunized, compared with non-immunized pa-
tients, has prompted two further clinical trials. A small trial has confirmed the effectiveness of
specific immunotherapy as adjunctive therapy for squamous cell carcinoma. A large multi-
center trial in Canada and the United States should be completed and open to analysis in 1984
and may shed light on the role oftumor-associated antigens in stimulating specific resistance to
lung cancer.
This paper reviews the results of nonspecific immunotherapy for lung cancer and
then presents data from the cooperative study between Washington and Ottawa, us-
ing a specific approach to boost the immune resistance of patients with stage I lung
cancer.
The pioneer in the use of living and later dead bacteria, whole or as extracts for
the treatment of cancer, was the surgeon William Coley [1,2]. Such material was
given into the tumor, subcutaneously or intravenously. This therapy, initiated
before the advent of radiotherapy or chemotherapy, was occasionally followed by
regression of even metastasizing tumors. Because of associated fever, nausea, diar-
rhea, and even collapse of the patient, Coley called his treatment "toxins," not im-
munotherapy. Loeb [3] conducted a survey ofthe efficacy ofColey's toxins, writing
to surgeons other than Coley. He concluded that, in not quite 5 percent of cases
treated, a positive result was obtained. In 1915 Harmer [4] made a critical analysis of
134 cases, confirmed microscopically to be malignant. He concluded that the round
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cell type of sarcoma had the greatest chance ofbenefit and that the small round cell
sarcoma had a much greater chance ofregression. In 1969 the conditions considered
necessary to allow success with Coley's toxins were listed [5]. Essential would be
histologic evidence of a dense infiltrate of the tumor by lymphocytes and plasma
cells, representing an intense but arrested immune response by the host. We now
know that in lung cancer such a response is the exception, seen in only 16 percent of
cases [6]. Thus in 84 percent of cases the use of bacterial extracts would cause mor-
bidity but little benefit to the patient. This reasoning led to a search for more specific
means of boosting host immunity to lung cancer, and to cooperation between Ot-
tawa and Washington.
THE USE OF BACTERIA OR BACTERIAL PRODUCTS
AS ADJUNCTIVE THERAPY OF CARCINOMA OF THE LUNG
Bacille Calmette-Guerin (B.C.G.) Given by the Intradermal Route
A five-year controlled study of B.C.G. and radiotherapy in inoperable lung
cancer was reported by Pines [7]. Forty-eight patients received radiotherapy for ad-
vanced lung cancer. Thereafter 25 received B.C.G. regularly by Heaf gun; 23 pa-
tients received no B.C.G. Three years later all patients who received B.C.G. were
dead; 22 of 23 controls were dead.
Another five-year study was reported byEdwards et al. [8]. Sixty patients received
B.C.G. by subdermal injection, following surgery by one surgeon. Sixty consecutive
surviving patients served as controls. No statistical evidence was found that B.C.G.
influenced the survival rate nor was there any effect on involved lymph nodes or
small metastases.
A study of 92 patients, strictly randomized following surgical resection of the
tumor, was reported by Roscoe et al. [9]. Twenty-nine patients received B.C.G. by
Heaf gun, 26 patients by intradermal injection, and 37 control patients received
nothing. No significant difference in survival between the control group and the two
immunotherapy groups was observed.
B.C.G. Given by the Oral Route
Miller et al. [10] evaluated a controlled clinical trial of 308 patients. Of these 155
received oral B.C.G.; 153 control patients received nothing. Over a three- to five-
year follow-up no difference in survival was seen between the two groups.
B.C.G. Given Intra Pleurally
McKneally et al. [11] continue to report on the favourable effect ofpostoperative
B.C.G. in stage I lung cancer patients. Their latest data shows 11 of36 patients who
received B.C.G. having recurrences, compared to 20 of 36 control patients
(p = .003).
Lowe et al. [12] fail to confirm this favorable effect of intra-pleural B.C.G. in a
report of a controlled randomized clinical trial of92 patients. No evidence ofbenefit
was seen with a period of follow-up of 14 to 36 months. This is in contrast to the
striking difference between controls and the B.C.G. patients over a similar time
period reported earlier by McKneally and his colleagues [13]. No significant benefit
of intra-pleural B.C.G. has been reported [14] in a large multicenter trial sponsored
by the National Lung Cancer Study Group. A total of 383 stage I patients were ran-
domized to receive intra-pleural B.C.G. or saline. The 56 recurrences were nearly
equally distributed between the two groups.
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No significant benefit (p = .11) was reported by Wright et al. [15] in a study of
134 patients who received B.C.G. intra-pleurally compared to a group who received
placebo.
Intra-Pleural Corynebacterium Parvum
Stjernsward [16] has reported on a randomized clinical trial comparing intra-
pleural corynebacterium parvum (CP) versus placebo. Four hundred patients were
evaluable. CP was found to be detrimental to the disease-free interval for well and
moderately differentiated histologic diagnoses (p = 0.034). An increase in fever
following CP was associated with a decrease in the disease-free interval.
It is ofinterest that the reports ofnaturally occurring empyema following surgical
resection of lung cancer differ in their conclusions. The entire literature was re-
viewed by Brohee et al. [17]; six reports of individual cases and five reports of
original controlled studies. They concluded that the literature was contradictory due
to uncontrolled variables. In their own study 148 male patients on register were ex-
amined. In curative surgical resection empyema had no benefit on survival (14
cases). In reductive surgery (20 cases with empyema) survival time was shortened
(p = 0.025). A careful study was reported by Minasian et al. [18] of50 patients who
developed empyema after resection for lung cancer. Such patients were individually
paired with patients who had not suffered this complication. Pairs were matched for
age, sex, extent of operation, histology of the tumor, extent of primary spread, ex-
tent oflymphatic spread, and the use ofpostoperative radiotherapy. The results sug-
gested that any immunological suppression of carcinoma cells due to sepsis in the
pleural space was ineffective in prolonging survival
More optimistic has been the report ofYamamura et al. [19] on the use ofB.C.G.
cell wall skeleton. Some 455 patients with lung cancer treated by surgery, irradia-
tion, and/or chemotherapy were given B.C.G. cell wall, oil attached, intratumor-
ally, or intracutaneously. Historical controls were used and it was concluded that
survival was significantly prolonged (p = 0.0001).
Levamisole as Adjunctive Therapy ofCarcinoma of the Lung
Amery [20] has recently updated survival following the randomized trial of
levamisole given to 96 patients, with 115 patients receiving a placebo. Benefit was
seen in patients receiving a higher dose of levamisole, and was evident two years
after surgery. Four years following surgery no effect was discernible.
Anthony et al. [21], using the optimal dosage of levamisole, studied 318 patients
in a randomized blind trial. A significantly poorer survival for resected lung cancer
patients was seen in the patients who received levamisole, with a 15 percent excess of
deaths in those 99 patients.
Wright et al. [15] also report on shortened survival ofpatients who received intra-
pleural B.C.G. plus levamisole, compared to controls. They conclude that the com-
bination of levamisole and intra-pleural B.C.G. will be of no benefit.
THYMOSIN FRACTION V
In a study [22] of 46 patients with small cell lung cancer (SCLC) all were treated
vigorously with remission-induction chemotherapy. The patients were randomized
to receive twice weekly thymosin fraction V 60 mg/m2, 20 mg/m2, or no thymosin,
during the initial six weeks ofchemotherapy. Individuals receiving 60 mg/m2 had a
significantly superior survival experience (p = .017). All but one of the 18 patients
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who received 60 mg/m2 are now dead, as are all those who received no thymosin or
the lower dose of thymosin.
SUMMARY
The earlier enthusiasm for the use of bacterial products as adjuvants in treating
lung cancer has waned, and one can see why. The reported effectiveness of
levamisole has not been confirmed and confirmation of the effectiveness of
thymosin in small cell lung cancer has yet to come, as emphasized by Cohen [23].
The Rationalefor Specific Immunotherapy ofLung Cancer
When the clinical trial that will be described was designed in 1972 it was based
upon the following observations. Healthy animals can be induced to mount a selec-
tive and destructive immunologic attack on various target organs if these animals
were immunized with an homogenate of Freund's complete adjuvant plus appropri-
ate target organ antigen. Thus encephalomyelitis, neuritis, uveitis, thyroiditis, and
orchitis could be induced [24]. The correlation between the appearance of a delayed
hypersensitivity reaction (DHR) to the target antigen in skin testing and the onset of
clinical disease was convincing [24]. The intensity ofthe DHR predicted the severity
of the immunologically induced damage [25]. Such damage could be transferred by
sensitized cells but not by serum; see the review by Waksman [24]. The importance
of the DHR as an indicator ofimmunologic reactivity had been clearly shown in the
classic paper ofBrent et al. in 1958 [26]. These authors showed that soluble antigens,
obtained by hypotonic shock following sonication, derived from allogeneic skin
grafts, gave a DHR on skin testing the recipient animal. The strength of this DHR
reflected the intensity of the graft rejection. Where the graft was strongly antigenic
the DHR to the soluble antigen was intense and rejection of the graft was rapid.
When weak antigenic barriers were tested the DHR to the target antigen was weak
and the tempo of rejection was sluggish.
It was clear that if one were to prepare soluble antigens from the surface of lung
cancer cells they would be relevant ifthey induced delayed hypersensitivity reactions
in patients with lung cancer and not in control patients. Furthermore, if one were to
use such antigens in order to boost cellular reactions of the host to residual
microscopic foci following curative surgery they would have to be free of organ an-
tigen, to avoid the induction ofpneumonitis. If allogeneic antigens were to be used,
cross reactivity would have to be shown. Such antigens have been identified for
squamous cell carcinoma, adenocarcinoma, large and small cell anaplastic car-
cinoma of the lung [27,28,29]. Since the initiation of the clinical trial in Ottawa in
1973, further evidence has accumulated that lung cancer cells are immunogenic.
Tumor-associated antigens have been detected in alveolar cell carcinoma [30],
adenocarcinoma [31,32,33,34], and squamous cell carcinoma [31,33,35,36,37,38].
Onco fetal antigens have also been described [31,33,34,36,37,39]. Cross reactivity of
common tumor associated antigens is seen in human lung cancers [27,29] and also in
animal models of carcinogen-induced lung cancer [40,41,42,43]. Low pH elution
techniques have been used to isolate immunoglobulins from lung cancer tissue and
pleural effusions [44]. Such antibodies reacted in significant titers with cells of
squamous cell carcinoma and adenocarcinomas but not with cells ofnormal adult or
fetal lung or ofnon-pulmonary tumors [45]. Various techniques in vitro have shown
lymphocyte response of cancer patients to lung tumor-associated antigens: lym-
phoblastogenesis [46,47,48], leucocyte migration inhibition [49,50,51,52], leucocyte
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adherence inhibition [53,54], and lymphocytotoxicity to autologous tumor cell
suspensions [55].
We chose to use high dose methotrexate (with citrovorum rescue) before im-
munization in some patients because this drug induces rebound overshoot of in vitro
lymphocyte performance [28]. For this reason we used as controls patients who were
not immunized but who received the drug in an identical fashion. In such patients
such a short course of the drug alone was anticipated to have no effect on patient
mortality.
METHODS AND MATERIALS
The study was opened in March 1973 and closed in September 1976.
PATIENT SELECTION
Patients were drawn from those having surgical removal oftheir tumor at the Ot-
tawa Civic Hospital, the National Defence Medical Centre, Ottawa, and the Ottawa
General Hospital. Careful staging for TNM [56] was assured by preoperative
radiography, scans, mediastinoscopy, and postoperative consideration of the notes
ofthe surgeon and pathologist. Fifty-two patients with Stage I disease are evaluated.
Ofthese, 16 patients acted as a concomitant control group; they were operated upon
by the same surgeons. The remaining 36 patients were randomized into one ofthree
treatment groups.
Group I-Eight patients who received methotrexate (MTX) followed by
citrovorum rescue once a month, for three months.
Group II- Immunotherapy. Fifteen patients who received allogeneic Tumor
Associated Antigen (matched for histology) homogenized with Freund's complete
adjuvant (FCA) once a month for three months.
Group III-Immunochemotherapy. Thirteen patients who were immunized seven
to nine days after administration of MTX with citrovorum rescue once a month for
three months.
In Table I are summarized all the relevant characteristics of the patients with
Stage I disease.
Dose ofAntigen
The preparation and characterization of antigens used for skin testing and im-
munization have been reported in detail [27].
TUMOR-ASSOCIATED ANTIGENS (TAA)
The mean total quantity of TAA given to patients in the immunotherapy group
was 1,495 ,tg, (range 1,125 /g to 2,200Ag). The mean total quantity ofTAA given to
the immunochemotherapy groups was 1,610 jig (range 900 to 3,000p/g). An average
of500Ag ofantigen in 0.5 ml was homogenized with an equal volumeofFCA(Difco
Laboratories, Detroit, MI) which contains 10 mg of killed mycobacterium hominis
per 10 ml, made up to 8.5 Bayol-F (mineral oil), and 1.5 ml Arlacel A (mannide
mono-oleate). The homogenate was given intra-dermally into the deltoid region of
the arm, the thigh, and again the arm at monthly intervals. Ulcers developed slowly
at the site ofinjection with erythema and thinning ofthe skin, ulceration at seven to
ten days, and showed gradual healing over months. They looked unsightly yet caused
very little discomfort unless they became infected. Such superficial infection
responded quickly to oral erythromycin. Occlusive dressings with sterile vaseline
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TABLE 1
Data on the Three Groups of Patients: Stage I
Chemotherapy and Concomitant Controls
Immunotherapy and Immunochemotherapy
MTX and Controls Immunotherapy Immunochemotherapy
Total patients 24 15 13
Male 19 11 9
Median age 57 55 57
Age range 39 to 74 yr 46 to 71 yr 45 to 66 yr
Performance status 0 3 5 3
At surgery 1 21 10 10
Total pneumonectomy 6 2 5
Right sided 14 7 5
Hilar node involvement 3 1 2
Cell Type
Epidermoid well
differentiated 9 7 5
Epidermoid poorly
differentiated 3 1 4
Adenocarcinoma 10 4 4
Anaplastic large cell 1 2 0
Anaplastic small cell 1 0 1
0, asymptomatic
1, symptomatic ambulant
gauze were useful for the first two months. Healing was completed by seven to 12
months.
Methotrexate (Lederle Laboratories) was given by rapid intravenous infusion, 300
mg and then 700 mg was infused over a period of six hours. A normal creatinine
clearance was mandatory and the urine was alkalinized by giving sodium bicar-
bonate 1.2 gm q6h per os, starting 24 hours before the infusion and continuing dur-
ing the folinic acid rescue period of60 hours (12 mg i.m. every six hours). The urine
pH was monitored q6h to ensure that the pH remained above 6.
RESULTS
Non-Immunized Group. This group consisted of24 patients; 16 concomitant con-
trol patients and eight who received methotrexate. Nine control patients have died of
lung cancer at 8, 14, 17, 22, 30, 32, 46, 51, and 65 months. Of those who received
methotrexate, five have died of lung cancer at 6, 22, 24, 26, and 64 months.
Immunized Group. This consisted of 15 patients who received allogeneic antigen
and Freund's complete adjuvant, and 13 patients who received immunochemo-
therapy. Ofthe 15 who were immunized, five have died oflung cancer at 27, 40, 42,
and 72 months. This last patient had inoperable recurrence of squamous carcinoma
in his trachea in November 1977 and died on June 3, 1980, 31 months later. One pa-
tient had a stump recurrence at twenty months of her large cell carcinoma, received
cobalt treatment, and died four years later of respiratory failure, free of disease. A
third patient had recurrence of his squamous cell carcinoma at 12 months. A total
pneumonectomy was performed and he died of respiratory failure and pneumonia
31/2 years later, aged 73. At necropsy foci of squamous cell carcinoma were found at
the stump ofhis pneumonectomy, surrounded by adense desmoplastic reaction with
a moderate lymphocytic infiltrate.
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Of the 13 patients who received immunochemotherapy, one died of cerebral
metastases at 14 months of large cell carcinoma. A second patient developed a
stump recurrence of squamous cell carcinoma at three years and died three years
later of disseminated cancer. Two patients were free of disease at the time of their
death; one of cardiac arrest in bed, 39 months after surgery, the other of
staphylococcal septicemia, 51 months after surgery, aged 71.
SURVIVAL
In Table 2 the life-table survival experience is summarized as calculated by the
method of Cutler and Ederer [57]. Those patients who died a non-cancer death have
been handled as being lost to follow-up. Figure 1 shows the survival curves for the
control and treated groups, with the one-sided 95 percent confidence limits for the
control and treated groups.
The survival experience of the treated group may be seen to diverge significantly
from the control group beyond 24 months. While 96 percent of the immunized
group reached the second anniversary, only 72 percent of the controls did so. The
corresponding values for the fourth anniversary are 82 percent and 50 percent,
respectively. The overall comparison for the treated and control groups using
Gehan's generalized Wilcoxon test [58] yielded a statistical significance ofp < .001.
Late Skin Testing with TAA: Following curative resection oflung, cancer patients
were skin tested with soluble tumor-associated antigen, derived in most instances
from allogeneic tumors, matched as closely as possible with the histology of the
resected tumor. The usual skin test dose was 100Ag in 0.1 ml. Not all patients could
be tested in the later months after surgery; some died, some refused, and for others,
distance from Ottawa made such testing impractical.
Non-Immunized Group. Stage I: Twelve patients were tested. Seven patients gave
a weak to moderate reaction to tumor antigen; one of these patients died of lung
cancer seven months later. Five patients gave no reaction on testing with tumor an-
tigen, yet were able to give a positive reaction to at least one recall bacterial antigen;
thus they were not completely anergic. Four of these patients died of lung cancer, 2,
7, 18, and 23 months after testing. Details of these skin tests are given in Table 3.
Immunized Group: Eleven patients were tested at varying intervals following
TABLE 2
Life Table Survival Experience of the Non-Immunized and Immunized Groups
The 95 percent one-sided confidence limits for each group are also shown.
MTX and Controls Immunotherapy and Immunochemotherapy
9507 One-Sided CL 95% One-Sided CL
Po 6 1.00 1.00 1.00 1.00
P12 .91 1.00 1.00 1.00
P18 .86 .97 .96 .89
P24 .72 .82 .96 .89
P30 .63 .76 .92 .84
P36 .54 .69 .92 .84
P42 .54 .69 .85 .74
P48 .50 .65 .82 .70
P54 .46 .61 .78 .65
P60 .46 .61 .78 .65
P66 .35 .51 .78 .65
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SEPTEMBER 1st 1980
STAGE I LUNG CANCER
IMMUNO
+
IMMUNO CHEMO
MTX+CONTROLS
GEHAN'S GENERALIZED WILCOXON TEST
p< O.001
6 12 18 24 30 36 42 48 54
PERIOD OF OBSERVATION (MONTHS)
60 66
FIG. 1. This is a graphic
representation ofthetwo sur-
vival curves. A significant
separation of the curves is
seen beyond 2 years to 5 ½/2
years.
surgery, for 13 skin tests. All patients gave a positive reaction and two died of lung
cancer 13 and 32 months later. The mean strength of these reactions is three times
greater than those in the non-immunized group. Details are given in Table 4.
Immunochemotherapy Group: Nine patients were tested following surgery for a
total of 16 tests. One patient died ofcerebral metastases four months after testing. A
second patient died of staphylococcal septicemia 26 months after testing, age 71,
clinically free of disease. Much stronger reactions are seen in this group, earlier and
maintaining strength with time (Table 5). Patient number 4 was tested 51/2 years
TABLE 3
Late Testing of Stage I Patients with Tumor-Associated Antigens (TAA)
Matched for Histology of the Primary Tumor
(Non-Immunized: Control or Methotrexate-treated patients)
Tested months Recall
post-operatively Antigen TAA DHR Status
Controls
A, 4 mo Adeno 5 x 5 Alive 37 mo
B, 15 mo Large cell 10 x 8 Dead 22 mo
Anaplastic
C, 31 mo Squamous 8 x 8 Alive 65 mo
D, 32 mo +ve Squamous Neg. Dead 39 mo
E, 42 mo Squamous 5 x 5 Alive 77 mo
MTX
F, 3 mo Squamous 16 x 16 Alive 56 mo
G, 4 mo +ve Alveolar Neg. Dead 27 mo
H, 6 mo +ve Squamous Neg. Dead 24 mo
I, 12 mo +ve Squamous Neg. Alive 52 mo
J, 12 mo Adeno 16 x 16 Alive 53 mo
K, 20 mo +ve Adeno Neg. Dead 22 mo
L, 30 mo Adeno 9 x 9 Alive 70 mo
Total: 12 Mean, 17.36 mo DHR: mm of induration at 48 hr Mean 5.75 mm
DHR positive to soluble cancer antigen 1/7 dead
DHR negative to soluble cancer antigen 4/5 dead
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TABLE 4
Late Testing of Stage I Patients with TAA
Tested months
post-operatively TAA DHR Status
Immunized Patients
M, 4mo Squamous 14 x 11
40 mo Squamous 40 x 35 Alive 44 mo*
N, 5 mo Alveolar 18 x 11 Alive 32 mo
0, 6 mo Adeno 13 x 11 Alive 35 mo
P, 8 mo Squamous 36 x 27 Alive 41 mo
Q, 10 mo Squamous 12 x 12 Dead 42 mo
R, 13 mo Autologous 10 ug 16 x 15
36 mo Autologous 20 ug 43 x 36 Alive 45 mo*
S, 17 mo Adeno. (autologous) 7 x 7 Alive 57 mo
T, 18 mo Squamous 7 x 5 Alive 57 mo
U, 25 mo Anaplastic 13 x 13 Alive 67 mo
V, 27 mo Squamous 16 x 16 Dead 40 mo
W, 29 mo Squamous 8 x 7 Alive 55 mo
Total: 11 Mean, 17 mo DHR: mm of induration at 48 hr Mean 17.9 mm 2/11 positive pa-
tients died of lung cancer
*Note the increase of reactivity to antigen over a period of three years.
following immunization and gave 20 x 20 mm of induration to 100 ,tg of
autologous antigen that had been stored at -800C. The mean diameter of these
delayed hypersensitivity reactions was 32 mm, double that of the immunized group
and six times as strong as the mean reaction, in the control non-immunized group.
TABLE 5
Late Testing of Stage I Patients with TAA
(Immunochemotherapy patients)
TAA DHR Status
MTX-Immunized
1. 3 mo Squamous 77 x 63 *
4 mo 10 x 10
36 mo 45 x 31 Alive 44 mo
2. 3 mo Squamous 9 x 8
20 mo Squamous 20 x 19
Adeno 22 x 21 Alive 29 mo**
3. 10 mo Squamous 11 x 11 Dead 14 mo
4. 3 mo Squamous 40 x 40 *
16 mo Anaplastic (autol) 40 x 40
47 mo Anaplastic (autol) 30 x 30 Alive 56 mo
5. 18 mo Adeno (autol) 14 x 12 Alive 58 mo
6. 22 mo Squamous 18 x 16 Alive 62 mo
7. 23 mo Adeno 10 x 10 Alive 62 mo
8. 24 mo Squamous 25 x 33 Dead 50 mo
(non-cancer
death)
9. 25 mo Adeno 55 x 55
56 mo Adeno 27 x 22 Alive 65 mo
Total: 9 Mean, 19 mo autol: Autologous antigen 1/9 positive patients died of lung cancer
*Note the strong reactivity relatively early following the combination ofmethotrexate and immunization.
**This patient had a primary squamous adenocarcinoma and was late tested for each antigen.
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DISCUSSION
A clear correlation between resistance to tumor growth and a delayed hypersen-
sitivity reaction to soluble tumor-associated antigens has been shown by several
workers in experimental animal tumor systems [59,60,61,62]. In general such
delayed hypersensitivity reactions last for 28-30 days. We believe that in our patients
persistence of such hypersensitivity reactions to tumor antigens for five years or
more is a sign of prolonged resistance to tumor growth.
The survival ofour non-immunized patients compares almost exactly with the sur-
vival of all patients entered into the large multicenter trial of oral B.C.G. in Canada
from 1973 to 1976 [10]. The significant improvement in the immunized group's sur-
vival may reflect resistance to tumor growth. Four patients had local recurrence of
cancer yet survived 31, 36, 42, and 48 months following this recurrence and in three
no chemotherapy was given at any time. This long survival is in direct contrast to the
study of Green and Kern [63]. Of 1,018 patients followed over a 13-year period, 46
had locally recurrent lung cancer. Median survival for those patients was 11 months
following recurrence, and only 5 percent survived three years or more.
In this trial it was decided to give the tumor-associated antigens homogenized with
Freund's complete adjuvant since this is the practice in inducing auto-immune target
organ damage and delayed hypersensitivity reactions to the target organ antigen. It
is recognized that resistance to adenovirus oncogenesis has been shown ifthe antigen
and Freund's complete adjuvant are given separately in hamsters, up to five days
after virus inoculation [64]. Strong delayed hypersensitivity reactions can be induced
in guinea pigs by using antigen and adjuvant homogenized or separately with a very
wide range of antigen, 2 yg to 10 mg [65]. The favourable survival of patients with
stage I squamous cell lung cancer [66] receiving Freund's complete adjuvant and
separate doses of antigen, as skin tests, from 200 to 400,g, in the first four months,
may indicate that the amount of tumor-associated antigen required is less than had
been anticipated in the phase II Ottawa trial. A current multicenter trial in Canada
and the United States should shed further light on this, as those patients randomized
to receive Freund's complete adjuvant alone will not receive tumor-associated an-
tigens as skin tests during the first year. Whether such nonspecific therapy will be ef-
fective in prolonging survival in such patients remains to be seen.
Conclusion: Active immunotherapy using tumor-associated antigens appears ef-
fective in prolonging survival ofpatients with Stage I lung cancer, following curative
surgery.
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